Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07301320Phase 2Recruiting

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

Role: collaborator

NCT07024589Phase 1Completed

First-in-Human Trial of Oral AN2-502998

Role: lead

NCT06089668Completed

An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis

Role: lead

NCT05327803Phase 2Terminated

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

Role: lead

NCT04892641Phase 1Completed

Phase 1 Study of Epetraborole Tablets

Role: lead

NCT05995444Phase 1Completed

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

Role: lead

NCT05283746Phase 1Completed

A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function

Role: lead

All 7 trials loaded